Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids (Q43505948)

24 November 2017

title

Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids (English)

1 reference

24 November 2017

0 references

1 reference

J C Virchow

1

1 reference

24 November 2017

A Prasse

2

1 reference

24 November 2017

I Naya

3

1 reference

24 November 2017

L Summerton

4

1 reference

24 November 2017

A Harris

5

1 reference

24 November 2017

language of work or name

English

0 references

publication date

1 August 2000

1 reference

American Journal of Respiratory and Critical Care Medicine

24 November 2017

published in

1 reference

24 November 2017

volume

162

1 reference

24 November 2017

issue

2 Pt 1

1 reference

24 November 2017

page(s)

578-585

1 reference

The preclinical pharmacology of ICI 204,219. A peptide leukotriene antagonist

24 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.162.2.9905041

Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.162.2.9905041

Lung function improvement in asthma with a cysteinylleukotriene receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.162.2.9905041

Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.162.2.9905041

Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.162.2.9905041

Effect of zafirlukast (Accolate) on cellular mediators of inflammation: bronchoalveolar lavage fluid findings after segmental antigen challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.162.2.9905041

Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.162.2.9905041

Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.162.2.9905041

Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.162.2.9905041

Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.162.2.9905041

Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. International Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.162.2.9905041

Effect of oral prednisone on airway inflammatory mediators in atopic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.162.2.9905041

Inhibition of eicosanoid biosynthesis by glucocorticoids in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.162.2.9905041

Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.162.2.9905041

The Pivotal Role of 5-Lipoxygenase Products in the Reaction of Aspirin-sensitive Asthmatics to Aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.162.2.9905041

10.1164/AJRCCM.162.2.9905041

21 January 2018

Identifiers

DOI

1 reference

24 November 2017

1 reference